Dalbergia sissoo Roxb. is one of the promising multipurpose tree species of South Asia. Most of the plantations of D. sissoo from seeds are facing severe threats due to the die-back disease, which ultimately causes de...Dalbergia sissoo Roxb. is one of the promising multipurpose tree species of South Asia. Most of the plantations of D. sissoo from seeds are facing severe threats due to the die-back disease, which ultimately causes death of this potential tree-species within a few months. Vegetative propagation could avoid the die-back disease. Thirty mother trees of different age-groups of D. sissoo were selected for evaluating the rooting behaviour of branch cuttings from D. sissoo as influenced by auxins （IAA or IBA at 100, 200, 500 mg·L^-1）, ages of mother trees （10, 4 and 2 years old） and different environment conditions, i.e., different mediums （soil and sand） or light conditions （in shade and open condition）. The results show that application of IAA and IBA induced more numbers of cuttings （collected from 10-year-old mother trees） to root compared to control. Branch cuttings of D. sissoo collected from 10-year-old mother trees and planted in soil bed in open conditions had 100.0% of cuttings to root in IAA （100 mg·L^-1） and IBA （200 mg·L^-1） treatments. Both rooting medium （Soil and sand） influenced significantly （p〈0.05） on rooting response of branch cuttings. Soil medium was found to achieve maximum no. of branch cuttings to root, compared to sand medium.展开更多
In boys, central precocious puberty （CPP） is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years. In the last years, relevant improvements in the trea...In boys, central precocious puberty （CPP） is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years. In the last years, relevant improvements in the treatment of CPP have been achieved. Because CPP is rare in boys, the majority of papers on this issue focus on girls and do not address specific features of male patients regarding end results and safety. In the present paper, recent advances of CPP management with GnRH analogs in men are summarized. End results in untreated and treated patients are also reviewed by an analysis of the recently published literature on treatment of CPP in men. The available data indicate that therapy with GnRH analogs can improve final height into the range of target height without significant adverse short-term and long-term effects, but longer follow-up of larger series of patients is still required to draw definitive conclusions.展开更多
AIM： To determine the relative risk of selected serious outcomes with variations in use of menopausal hormone treatment （MHT）. METHODS： A cohort of 489 women, randomly recrui-ted at age 40-79 years, from a longitu...AIM： To determine the relative risk of selected serious outcomes with variations in use of menopausal hormone treatment （MHT）. METHODS： A cohort of 489 women, randomly recrui-ted at age 40-79 years, from a longitudinal study of urbanised population was a study group and was followed for 14 years. Four selected outcomes （coronary artery disease, stroke, peripheral artery disease, breast cancer） were tested. Each woman on entry to the study was interviewed by a dedicated medical practitioner, and data on menstrual and menopausal history and health status were obtained. Outcome information was ascertained by questionnaire and medical reports from attending medical practitioners. In case of death, cause of death was checked with the Registry of Births, Deaths, Marriages and Divorce. This information was available for all women. An ever-user of MHT was defined as use for 6 mo or more at any time during the study. A late start of MHT was defned as 3 years or more from onset of menopause. The generalised linear statistical package was used to examine the data; univariate logistic regression models were used to describe the relationship between patient characteristics and a disease outcome, followed by stepwise multi variate analysis, controlling for age, lifestyle factors and co-morbidities.RESULTS： The risk of ever-use of MHT was signifcantly increased only for peripheral artery disease （RR = 2.16; 0.99, 4.71; P = 0.05）, and not for coronary artery disease, stroke and breast cancer. A late start of MHT （three years or more from onset of menopause） was associated with signifcantly increased risks for coronary artery disease （RR = 2.56; 1.15, 5.72; P = 0.02） and peripheral artery disease （RR = 4.42; 1.55, 12.64; P = 0.005）, and use after age 60 years with signifcantly increased risks for coronary artery disease （RR = 4.98; 2.19, 11.55; P 〈 0.001）, stroke （RR = 2.99; 1.11, 8.08; P = 0.03） and peripheral artery disease （RR = 4.18; 1.24, 14.14; P = 0.02）. Use up to 10 years was not associated with signifcant risk for all outcomes. These risks were confrmed by stepwise multi variate analysis, adjusting for age at recruitment, body mass index, smoking, physical activity and alcohol use, and existing diabetes, mellitus, hypertension and hypercholesterolaemia. Regardless of variations in use, risk for breast cancer was not found. CONCLUSION： The study confirms ever-use of MHT affected only risk of peripheral artery disease; but some use variations could have adverse effects.展开更多
Before the positive results recently obtained with multitarget tyrosine kinase inhibitor sorafenib,there was no standard systemic treatment for patients with advanced hepatocellular carcinoma(HCC).Sex hormones recepto...Before the positive results recently obtained with multitarget tyrosine kinase inhibitor sorafenib,there was no standard systemic treatment for patients with advanced hepatocellular carcinoma(HCC).Sex hormones receptors are expressed in a significant proportion of HCC samples.Following preclinical and epidemiological studies supporting a relationship between sex hormones and HCC tumorigenesis,several randomized controlled trials (RCTs)tested the efficacy of the anti-estrogen tamoxifen as systemic treatment.Largest among these trials showed no survival advantage from the administration of tamoxifen,and the recent Cochrane systematic review produced a completely negative result.This questions the relevance of estrogen receptor-mediated pathways in HCC.However,a possible explanation for these disappointing results is the lack of proper patients selection according to sex hormones receptors expression,but unfortunately the interaction between this expression and efficacy of tamoxifen has not been studied adequately.It has been also proposed that negative results might be explained if tamoxifen acts in HCC via an estrogen receptor-independent pathway,that requires higher doses than those usually administered, but an Asian RCT conducted to assess dose-response effect was completely negative.Interesting,preliminaryresults have been obtained when hormonal treatment (tamoxifen or megestrol)has been selected according to the presence of wild-type or variant estrogen receptors respectively,but no large RCTs are available to support this strategy.Negative results have been obtained also with anti-androgen therapy.In conclusion,there is no robust evidence to consider HCC a hormone-responsive tumor.Hormonal treatments should not be part of the current management of HCC.展开更多
Estrogen produces several beneficial effects in healthy neurological tissues and exhibits cardioprotective effects.Hormone therapy has been widely used to treat menopausal estrogen deficiency for more than 80 years.De...Estrogen produces several beneficial effects in healthy neurological tissues and exhibits cardioprotective effects.Hormone therapy has been widely used to treat menopausal estrogen deficiency for more than 80 years.Despite high initial expectations of cardioprotective effects,there has been substantial distrust following important randomized clinical trials,such as the Women’s Health Initiative.Subsequently,the timing of treatment in relation to the onset of menopause came under consideration and led to the proposal of the timing hypothesis,that early initial treatment is important,and benefits are lost as the timing since menopause becomes prolonged.Subsequent analyses of the Women’s Health Initiative data,together with more recent data from randomized and observational trials,consistently show reductions in coronary heart disease and mortality in younger menopausal women.Regarding cognitive function,the timing hypothesis is consistent with observations from basic and animal studies.There is some clinical evidence to support the benefits of hormonal therapy in this context,though skepticism remains due to the paucity of clinical trials of substantial length in younger menopausal women.It is likely that the effects of estrogens on cognitive performance are due to rapid mechanisms,including mechanisms that influence Ca2+homeostasis dynamics,provide protection in a hostile environment and reduce inflammatory signals from neural tissues.In the future,inflammatory profiles accounting for early signs of pathological inflammation might help identify the‘window of opportunity’to use estrogen therapy for successful cognitive protection.展开更多
In recent years,many therapeutic advances have been made in the management of castration-resistant prostate cancer,with the development and approval of many new drugs.The androgen receptor(AR)is the main driver in pro...In recent years,many therapeutic advances have been made in the management of castration-resistant prostate cancer,with the development and approval of many new drugs.The androgen receptor(AR)is the main driver in prostate cancer growth and progression and the most effective therapeutic agents are still directed against this pathway.Among these,new generation hormonal agents(NHA)including enzalutamide,abiraterone acetate,apalutamide,and darolutamide have shown to improve overall survival and quality of life of prostate cancer patients.Unfortunately,despite the demonstrated benefit,not all patients respond to treatment and almost all are destined to develop a resistant phenotype.Although the resistance mechanisms are not fully understood,the most studied ones include the activation of both dependent and independent AR signalling pathways.Recent findings about multiple growth-promoting and survival pathways in advanced prostate cancer suggest the presence of alternative mechanisms involved in disease progression,and an interplay between these pathways and AR signalling.In this review we discuss the possible mechanisms of primary and acquired resistance to NHA with a focus on AR independent pathways.展开更多
Objective:To explore the effect of Wulong Dan (WLD) on treatment of acute cerebral infarction and change of hormones in hypothalamus-pituitary-thyroid axis. Methods:Thirty five cases of the treated group treated with ...Objective:To explore the effect of Wulong Dan (WLD) on treatment of acute cerebral infarction and change of hormones in hypothalamus-pituitary-thyroid axis. Methods:Thirty five cases of the treated group treated with WLD by taken orally and 31 cases of the control group treated with nimoton taken orally. And dextran was given intravenously to both groups. Blood level of triiodothyronine (T3), free triiodothyronine (FT3), thyroxine (T4), free throxine (FT4) and thyroid stimulating hormone (TSH) of all patients were determined before and after treatment by radioimmunoassay. Results: After 4 weeks of treatment, there were significant difference between the treated group and the control group in cure rate, markedly effective rate,cure score and disappearance of clinical symptoms (P < 0. 01 ). The levels of T3, FT3,TSH of all patients were lower than those of the normal control before treatment. After treatment with WLD and dextran, the abovementioned indexes turned to normal. Conclusions: WLD has a significant effect on patients with cerebral infarction on the basis of improved microcirculation induced by dextran. It also has regulatory effect on the hypothalamuspituitary-thyroid axis disorder so as to be helpful in maintaining the homeostasis.展开更多
基金supported by Indian Council ofForestry Research and Education (ICFRE), Dehradun, 248 006, Uttarakhand, India
文摘Dalbergia sissoo Roxb. is one of the promising multipurpose tree species of South Asia. Most of the plantations of D. sissoo from seeds are facing severe threats due to the die-back disease, which ultimately causes death of this potential tree-species within a few months. Vegetative propagation could avoid the die-back disease. Thirty mother trees of different age-groups of D. sissoo were selected for evaluating the rooting behaviour of branch cuttings from D. sissoo as influenced by auxins （IAA or IBA at 100, 200, 500 mg·L^-1）, ages of mother trees （10, 4 and 2 years old） and different environment conditions, i.e., different mediums （soil and sand） or light conditions （in shade and open condition）. The results show that application of IAA and IBA induced more numbers of cuttings （collected from 10-year-old mother trees） to root compared to control. Branch cuttings of D. sissoo collected from 10-year-old mother trees and planted in soil bed in open conditions had 100.0% of cuttings to root in IAA （100 mg·L^-1） and IBA （200 mg·L^-1） treatments. Both rooting medium （Soil and sand） influenced significantly （p〈0.05） on rooting response of branch cuttings. Soil medium was found to achieve maximum no. of branch cuttings to root, compared to sand medium.
文摘In boys, central precocious puberty （CPP） is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years. In the last years, relevant improvements in the treatment of CPP have been achieved. Because CPP is rare in boys, the majority of papers on this issue focus on girls and do not address specific features of male patients regarding end results and safety. In the present paper, recent advances of CPP management with GnRH analogs in men are summarized. End results in untreated and treated patients are also reviewed by an analysis of the recently published literature on treatment of CPP in men. The available data indicate that therapy with GnRH analogs can improve final height into the range of target height without significant adverse short-term and long-term effects, but longer follow-up of larger series of patients is still required to draw definitive conclusions.
文摘AIM： To determine the relative risk of selected serious outcomes with variations in use of menopausal hormone treatment （MHT）. METHODS： A cohort of 489 women, randomly recrui-ted at age 40-79 years, from a longitudinal study of urbanised population was a study group and was followed for 14 years. Four selected outcomes （coronary artery disease, stroke, peripheral artery disease, breast cancer） were tested. Each woman on entry to the study was interviewed by a dedicated medical practitioner, and data on menstrual and menopausal history and health status were obtained. Outcome information was ascertained by questionnaire and medical reports from attending medical practitioners. In case of death, cause of death was checked with the Registry of Births, Deaths, Marriages and Divorce. This information was available for all women. An ever-user of MHT was defined as use for 6 mo or more at any time during the study. A late start of MHT was defned as 3 years or more from onset of menopause. The generalised linear statistical package was used to examine the data; univariate logistic regression models were used to describe the relationship between patient characteristics and a disease outcome, followed by stepwise multi variate analysis, controlling for age, lifestyle factors and co-morbidities.RESULTS： The risk of ever-use of MHT was signifcantly increased only for peripheral artery disease （RR = 2.16; 0.99, 4.71; P = 0.05）, and not for coronary artery disease, stroke and breast cancer. A late start of MHT （three years or more from onset of menopause） was associated with signifcantly increased risks for coronary artery disease （RR = 2.56; 1.15, 5.72; P = 0.02） and peripheral artery disease （RR = 4.42; 1.55, 12.64; P = 0.005）, and use after age 60 years with signifcantly increased risks for coronary artery disease （RR = 4.98; 2.19, 11.55; P 〈 0.001）, stroke （RR = 2.99; 1.11, 8.08; P = 0.03） and peripheral artery disease （RR = 4.18; 1.24, 14.14; P = 0.02）. Use up to 10 years was not associated with signifcant risk for all outcomes. These risks were confrmed by stepwise multi variate analysis, adjusting for age at recruitment, body mass index, smoking, physical activity and alcohol use, and existing diabetes, mellitus, hypertension and hypercholesterolaemia. Regardless of variations in use, risk for breast cancer was not found. CONCLUSION： The study confirms ever-use of MHT affected only risk of peripheral artery disease; but some use variations could have adverse effects.
文摘Before the positive results recently obtained with multitarget tyrosine kinase inhibitor sorafenib,there was no standard systemic treatment for patients with advanced hepatocellular carcinoma(HCC).Sex hormones receptors are expressed in a significant proportion of HCC samples.Following preclinical and epidemiological studies supporting a relationship between sex hormones and HCC tumorigenesis,several randomized controlled trials (RCTs)tested the efficacy of the anti-estrogen tamoxifen as systemic treatment.Largest among these trials showed no survival advantage from the administration of tamoxifen,and the recent Cochrane systematic review produced a completely negative result.This questions the relevance of estrogen receptor-mediated pathways in HCC.However,a possible explanation for these disappointing results is the lack of proper patients selection according to sex hormones receptors expression,but unfortunately the interaction between this expression and efficacy of tamoxifen has not been studied adequately.It has been also proposed that negative results might be explained if tamoxifen acts in HCC via an estrogen receptor-independent pathway,that requires higher doses than those usually administered, but an Asian RCT conducted to assess dose-response effect was completely negative.Interesting,preliminaryresults have been obtained when hormonal treatment (tamoxifen or megestrol)has been selected according to the presence of wild-type or variant estrogen receptors respectively,but no large RCTs are available to support this strategy.Negative results have been obtained also with anti-androgen therapy.In conclusion,there is no robust evidence to consider HCC a hormone-responsive tumor.Hormonal treatments should not be part of the current management of HCC.
文摘Estrogen produces several beneficial effects in healthy neurological tissues and exhibits cardioprotective effects.Hormone therapy has been widely used to treat menopausal estrogen deficiency for more than 80 years.Despite high initial expectations of cardioprotective effects,there has been substantial distrust following important randomized clinical trials,such as the Women’s Health Initiative.Subsequently,the timing of treatment in relation to the onset of menopause came under consideration and led to the proposal of the timing hypothesis,that early initial treatment is important,and benefits are lost as the timing since menopause becomes prolonged.Subsequent analyses of the Women’s Health Initiative data,together with more recent data from randomized and observational trials,consistently show reductions in coronary heart disease and mortality in younger menopausal women.Regarding cognitive function,the timing hypothesis is consistent with observations from basic and animal studies.There is some clinical evidence to support the benefits of hormonal therapy in this context,though skepticism remains due to the paucity of clinical trials of substantial length in younger menopausal women.It is likely that the effects of estrogens on cognitive performance are due to rapid mechanisms,including mechanisms that influence Ca2+homeostasis dynamics,provide protection in a hostile environment and reduce inflammatory signals from neural tissues.In the future,inflammatory profiles accounting for early signs of pathological inflammation might help identify the‘window of opportunity’to use estrogen therapy for successful cognitive protection.
文摘In recent years,many therapeutic advances have been made in the management of castration-resistant prostate cancer,with the development and approval of many new drugs.The androgen receptor(AR)is the main driver in prostate cancer growth and progression and the most effective therapeutic agents are still directed against this pathway.Among these,new generation hormonal agents(NHA)including enzalutamide,abiraterone acetate,apalutamide,and darolutamide have shown to improve overall survival and quality of life of prostate cancer patients.Unfortunately,despite the demonstrated benefit,not all patients respond to treatment and almost all are destined to develop a resistant phenotype.Although the resistance mechanisms are not fully understood,the most studied ones include the activation of both dependent and independent AR signalling pathways.Recent findings about multiple growth-promoting and survival pathways in advanced prostate cancer suggest the presence of alternative mechanisms involved in disease progression,and an interplay between these pathways and AR signalling.In this review we discuss the possible mechanisms of primary and acquired resistance to NHA with a focus on AR independent pathways.
文摘Objective:To explore the effect of Wulong Dan (WLD) on treatment of acute cerebral infarction and change of hormones in hypothalamus-pituitary-thyroid axis. Methods:Thirty five cases of the treated group treated with WLD by taken orally and 31 cases of the control group treated with nimoton taken orally. And dextran was given intravenously to both groups. Blood level of triiodothyronine (T3), free triiodothyronine (FT3), thyroxine (T4), free throxine (FT4) and thyroid stimulating hormone (TSH) of all patients were determined before and after treatment by radioimmunoassay. Results: After 4 weeks of treatment, there were significant difference between the treated group and the control group in cure rate, markedly effective rate,cure score and disappearance of clinical symptoms (P < 0. 01 ). The levels of T3, FT3,TSH of all patients were lower than those of the normal control before treatment. After treatment with WLD and dextran, the abovementioned indexes turned to normal. Conclusions: WLD has a significant effect on patients with cerebral infarction on the basis of improved microcirculation induced by dextran. It also has regulatory effect on the hypothalamuspituitary-thyroid axis disorder so as to be helpful in maintaining the homeostasis.
